Amicus Therapeutics Inc (NASDAQ:FOLD) Short Interest Increased By 2.28%

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Logo

Investors sentiment decreased to 1.3 in 2018 Q2. Its down 0.53, from 1.83 in 2018Q1. It dropped, as 24 investors sold Amicus Therapeutics, Inc. shares while 45 reduced holdings. 29 funds opened positions while 61 raised stakes. 216.23 million shares or 0.98% more from 214.13 million shares in 2018Q1 were reported.
Valley Advisers owns 20 shares. Principal Fincl Group accumulated 0% or 148,699 shares. Sectoral Asset has invested 6.45% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Amalgamated Retail Bank reported 28,896 shares. Fincl Bank Of New York Mellon reported 2.05 million shares. Jefferies Ltd Liability holds 0% of its portfolio in Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 13,705 shares. 18,691 were reported by Jgp Gestao De Recursos Ltda. Jane Street Llc has invested 0% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Fortaleza Asset stated it has 9,250 shares. The New York-based Alliancebernstein L P has invested 0% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Berson And Corrado Llc holds 0.35% of its portfolio in Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 36,870 shares. 268,498 were reported by California Employees Retirement Systems. Bancorp Of America De holds 680,464 shares or 0% of its portfolio. 2.54 million are held by Eagle Asset. Aperio Group Inc Lc holds 0% or 15,354 shares.

Since July 2, 2018, it had 4 buys, and 3 selling transactions for $8.07 million activity. PERCEPTIVE ADVISORS LLC had bought 500,000 shares worth $6.00M on Wednesday, September 12. Andrews Kurt J. sold $78,166 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) on Monday, July 2.

The stock of Amicus Therapeutics Inc (NASDAQ:FOLD) registered an increase of 2.28% in short interest. FOLD’s total short interest was 26.32 million shares in December as published by FINRA. Its up 2.28% from 25.73M shares, reported previously. With 1.59M shares average volume, it will take short sellers 17 days to cover their FOLD’s short positions. The short interest to Amicus Therapeutics Inc’s float is 16.72%.

The stock decreased 4.25% or $0.44 during the last trading session, reaching $9.92. About 2.45 million shares traded. Amicus Therapeutics, Inc. (NASDAQ:FOLD) has declined 10.62% since December 8, 2017 and is downtrending. It has underperformed by 26.24% the S&P500.

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company has market cap of $1.88 billion. The Company’s principal product is the migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which has completed two global Phase III registration studies. It currently has negative earnings. The firm is also developing SD-101, which is in Phase III clinical study for the treatment of the genetic connective tissue disorder epidermolysis bullosa; and AT3375 to treat Parkinson's disease.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Ratings Coverage

Among 2 analysts covering Amicus Therapeutics (NASDAQ:FOLD), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. Amicus Therapeutics had 2 analyst reports since August 17, 2018 according to SRatingsIntel. The stock has “Neutral” rating by Chardan Capital Markets on Friday, August 17.

More notable recent Amicus Therapeutics, Inc. (NASDAQ:FOLD) news were published by: which released: “Tesla (TSLA) to Start Production at Shanghai by End of 2019 – Nasdaq” on December 07, 2018, also with their article: “Consolidated Research: 2018 Summary Expectations for Xencor, Cyclacel Pharmaceuticals, Amicus Therapeutics, Take-Two Interactive Software, CSG Systems International, and Vonage — Fundamental Analysis, Key Performance Indications – GlobeNewswire” published on December 04, 2018, published: “VIVO Cannabisâ„¢ Reports Record Revenue for Q3 2018 – Nasdaq” on November 30, 2018. More interesting news about Amicus Therapeutics, Inc. (NASDAQ:FOLD) were released by: and their article: “Wary of Trump’s USA, Central American migrants find only despair in Spain – Nasdaq” published on November 23, 2018 as well as‘s news article titled: “TerraForm Power Inc.’s European Acquisition Powers Strong Q3 Results – Nasdaq” with publication date: November 09, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.